Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study
NCT07527182
Artemisinin-resistant, Drug Resistance
Mersa, Tigray, Ethiopia
View Trial DetailsNCT Number: NCT04404582
The detection of Klebsiella pneumoniae virulence gene and antibiotics resistance gene takes a long time and high cost with equipment requirements. Distinguishing the Klebsiella pneumoniae by gene were late for clinical treatment. Therefore, the investigators aim to study the clinical characteristics of critically ill patients with Klebsiella pneumoniae infection which expressed different drug sensitivity test results.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Clinical data of adult patients in integrated ICUs of 6 hospitals of Fujian Province China from January 2015 to July 2019 were collected, who had been examined for sputum, urine, blood, pleural effusion, ascites, cerebrospinal fluid and wound secretions and other body fluid samples. And the results showed that Klebsiella pneumoniae was positive, including demographic data, underlying disease status, drug sensitivity test, infection-related indicators, life support, prognostic indicators.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 30 day
30-day survival rate
Time frame: about a mouth
the length that patients stay in ICU
Fujian Provincial Hospital
Other
Analysis of the Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection: A Multi-center Research in the Intensive Care Units
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07527182
Artemisinin-resistant, Drug Resistance
Mersa, Tigray, Ethiopia
View Trial DetailsNCT04990596
Drug Resistance
Paris, France
View Trial DetailsNCT04833231
Chronic Disease, Chronic Kidney Disease
Konya, Turkey (Türkiye)
View Trial DetailsNCT04326868
Drug Resistance, Helminths Infection
Lambaréné, Moyen-Ogooué Province, Gabon
View Trial Details